NEW YORK – Guardant Health said Tuesday that it will establish an in-house liquid biopsy testing service, including Guardant360 CDx on-site analysis, within the Rome-based Agostino Gemelli University Polyclinic Foundation (Policlinico Gemelli) hospital system.
The financial details of the agreement were not provided.
"This partnership with Guardant Health represents a fundamental step for our hospital," Giovanni Scambia, scientific director of Policlinico Gemelli, said in a statement.
"We’re thrilled to partner with Policlinico Gemelli, empowering clinicians to swiftly detect tumor alterations with a blood test, guiding personalized treatments, and fueling research innovation," Helmy Eltoukhy, co-CEO of Guardant Health, said in a statement. "This collaboration brings us closer to our mission of ensuring all cancer patients worldwide have access to the latest advancements for optimal care."
Japan's Ministry of Health, Labour, and Welfare recently approved Guardant360 CDx as a companion diagnostic for Janssen Pharmaceutical's amivantamab-vmjw.